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Abstract
Introduction—This study estimated the percentage of breast cancer cases, total number of 
incident cases, and total annual medical care costs attributable to alcohol consumption among 
insured younger women (aged 18–44 years) by type of insurance and stage at diagnosis.
Methods—The study used the 2012–2013 National Survey on Drug Use and Health, cancer 
incidence data from two national registry programs, and published relative risk measures to 
estimate the: (1) alcohol-attributable fraction of breast cancer cases among younger women by 
insurance type; (2) total number of breast cancer incident cases attributable to alcohol 
consumption by stage at diagnosis and insurance type among younger women; and (3) total annual 
medical care costs of treating breast cancer incident cases attributable to alcohol consumption 
among younger women. Analyses were conducted in 2016; costs were expressed in 2014 U.S. 
dollars.
Results—Among younger women enrolled in Medicaid, private insurance, and both groups, 
8.7% (95% CI=7.4%, 10.0%), 13.8% (95% CI=13.3%, 14.4%), and 12.3% (95% CI=11.4%, 
13.1%) of all breast cancer cases, respectively, were attributable to alcohol consumption. 
Localized stage was the largest proportion of estimated attributable incident cases. The estimated 
total number of breast cancer incident alcohol-attributable cases was 1,636 (95% CI=1,570, 1,703) 
and accounted for estimated total annual medical care costs of $148.4 million (95% CI=$140.6 
million, $156.1 million).
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Conclusions—Alcohol-attributable breast cancer has estimated medical care costs of nearly 
$150 million per year. The current findings could be used to support evidence-based interventions 
to reduce alcohol consumption in younger women.
INTRODUCTION
In the U.S., more than 22,000 new cases of breast cancer are diagnosed among women aged 
<45 years (“younger women”) annually.1 Breast Cancer Education and Awareness Requires 
Learning Young Act of 2009, or EARLY Act (H.R. 1740, S. 994), and the Centers for 
Disease Control and Prevention (CDC)’s project has specifically focused on these younger 
women.2,3 Breast cancer in younger women is often characterized by aggressive tumor 
subtypes that are less likely to be amenable to treatment at the time of diagnosis and have 
poorer survival outcomes than older women.4–6 The disease affects younger women at a 
period in which most have family and social responsibilities and others may be completing 
their education and establishing economic independence. As a result, breast cancer in 
younger women is associated with substantial adverse health outcomes and economic 
burden.7
Alcohol consumption is a well-established, modifiable risk factor for breast cancer among 
all women, with an estimated 5%–9% increase in risk per drink per day.8–12 In addition, 
cohort studies have found supporting evidence linking alcohol intake to different subtypes of 
breast cancer, particularly estrogen receptor–positive/progesterone receptor–positive tumors 
compared to other subtypes.13–15 Furthermore, recent publications have provided more 
evidence that consumption of alcoholic beverages is causally associated with breast cancer, 
even at low to moderate levels of consumption.8–10,16,17
According to a national survey conducted in 2015, one in eight women aged 18–44 years 
engaged in binge drinking, which is defined by CDC as consuming four or more drinks per 
occasion in the last 30 days.18,19 In 2013, about 54% of women aged 18–44 years reported 
any alcohol use and the prevalence of excessive or binge drinking among these women was 
18.2%.20 The prevalence of alcohol consumption among the current birth cohort of younger 
women may not decrease as they grow older.19 Therefore, alcohol use and binge drinking 
among younger women is a public health problem. Several epidemiologic studies have 
found that risk for breast cancer increases with increasing alcohol intake.8,21 Because many 
young women drink, and some drink heavily, young adulthood is a vulnerable period for 
increasing the risk for developing breast cancer attributable to alcohol during their lifespan.
17,20
 Estimating the alcohol-attributable breast cancer incident cases in younger women by 
stage at diagnosis and by insurance status (Medicaid, private, and both groups together) can 
help quantify the burden of alcohol-attributable breast cancer in this vulnerable age group. In 
addition, no study has reported the medical care costs of treating younger women with 
alcohol-attributed breast cancer cases.
In the past, studies have examined the incidence and costs of breast cancer treatment in 
Medicaid and privately insured populations, but not by risk factor and stage at diagnosis.
22–26
 However, two recent studies have reported the costs of breast cancer treatment in 
younger women who are Medicaid beneficiaries or are privately insured by stage at 
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diagnosis, but did not account for risk factors such as alcohol (J Trogdon, University of 
North Carolina at Chapel Hill, unpublished observations, 2017).27
Given these gaps in the literature, the purpose of this study is to estimate the:
1. percentage of breast cancer cases attributable to alcohol consumption among 
younger women compared with older women;
2. total number of breast cancer incident cases attributed to alcohol; and
3. total annual medical care costs of treating these breast cancer incident cases 
attributable to alcohol consumption among younger women stratified by stage at 
diagnosis and insurance type, which includes private insurance, Medicaid, and 
both groups together.
Providing estimates for younger and older women by insurance type and by stage at 
diagnosis may help determine strategies that can be effectively used to reduce breast cancer 
incident cases attributable to alcohol use.
METHODS
Data from several sources were used to address the study objectives in three steps. In Step 1, 
the authors estimated the alcohol-attributable fraction (AAF; %) of breast cancer cases for 
women aged 18–44 years compared with those aged 45–64 years using an approach detailed 
in Ezzati et al.28 Additional technical details used in calculating AAFs for breast cancer 
cases are provided in Appendix A (available online). Specifically, the authors started by 
estimating the prevalence and distribution of alcohol consumption in women. They used data 
from the 2012–2013 National Survey on Drug Use and Health (NSDUH) to measure alcohol 
consumption by demographic and health insurance subgroups.29 The NSDUH protocol 
reviews the definition of a drink (e.g., can or bottle of beer, glass of wine or wine cooler), 
and then asks respondents to provide information about the quantity and frequency of 
consumed drinks. Using this information, it is assumed that each drink consists of 14 grams 
of ethanol,30 and the authors constructed a measure of alcohol consumption in average 
grams of ethanol consumed per day. NSDUH provides a sample of 105,417 people sampled 
from the civilian, non-institutionalized population aged ≥12 years from all the 50 states plus 
the District of Columbia. NSDUH collects data through face-to-face interviews with a 
representative sample of the population at the respondent’s place of residence.
More detailed information on the NSDUH survey design and content is available elsewhere.
29
 The AAF was calculated using data on the prevalence and distribution of alcohol 
consumption from NSDUH, coupled with an estimate of the relative risk (RR) of breast 
cancer associated with the volume of consumed alcohol. The estimated RR of breast cancer 
was calculated using a meta-analytic dose–response model,31 and data from the studies 
reviewed by Bagnardi and colleagues.32 As the majority of studies did not provide estimates 
separately for younger versus older women, the authors used an RR estimate of breast 
cancer for women of all ages and applied it to younger women.
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The AAFs were calculated separately for women with Medicaid and for those with private 
insurance. In calculating AAFs, the authors did not distinguish between excessive drinkers 
and moderate drinkers. This is because studies have reported that even at low levels of 
alcohol consumption there is a risk of developing breast cancer.33,34 Rather, they modeled 
the probability distribution over all levels of alcohol consumption. This incorporates into the 
analysis the notion that there may be a small risk of breast cancer associated with even a 
small amount of drinking.
In Step 2, the total number of breast cancer incident cases attributable to alcohol 
consumption was calculated by multiplying the estimated AAF of breast cancer cases 
obtained from Step 1 by the average number of incident breast cancer cases in the U.S. from 
2012 to 2013. Average number of incident cases was used to provide a robust estimate from 
NSDUH. The breast cancer incident cases were obtained from the U.S. Cancer Statistics 
combined data from CDC’s National Program of Cancer Registries and the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results program, which together cover 
nearly 100% of cancer incidence in the U.S. population (Appendix Table 1, available 
online). Only registries that met the U.S. Cancer Statistics publication criteria were included 
for estimation.35 The estimation was stratified by insurance type and by Surveillance, 
Epidemiology, and End Results-Summary Stage at diagnosis (local, regional, and distant).36 
The prevalence of Medicaid and private health insurance by stage of cancer was estimated 
using results from a recent paper.37
In Step 3, the annual medical care costs for alcohol-attributable breast cancer was estimated 
by multiplying the total number of breast cancer incident cases attributable to alcohol 
consumption by the incremental medical care costs associated with breast cancer treatment. 
The incremental medical care costs were obtained from two recent studies, which calculated 
the costs relative to healthy women within a 5-year age group (J Trogdon, University of 
North Carolina at Chapel Hill, unpublished observations, 2017).27 Details of the medical 
care costs are presented in Appendix Table 2 (available online). These incremental cost 
estimates represent the average amount of medical care costs incurred per patient due to 
breast cancer. The point estimates are averages by insurance status and stage. The analyses 
were conducted in 2016 and all costs were expressed in 2014 U.S. dollars.
The methods outlined in this paper involved combining data and evidence from disparate 
sources; therefore, a Monte Carlo simulation approach was used to assess uncertainty around 
all estimates and produced 95% CIs around all reported estimates.38 Appendix A4 and 
Appendix Tables 3 and 4 (available online) provide additional technical details around the 
distributional assumptions made in the Monte Carlo simulations.
RESULTS
The authors estimated that among younger women (aged 18–44 years) who are Medicaid 
beneficiaries, privately insured, and a combination of both, 8.7% (95% CI=7.4%, 10.0%), 
13.8% (95% CI=13.3%, 14.4%), and 12.3% (95% CI=11.4%, 13.1%) of all breast cancer 
cases are attributable to alcohol consumption, respectively (Table 1). For older women (aged 
45–64 years), the estimates were 6.9% (95% CI=6.2%, 7.5%), 7.3% (95% CI=6.8%, 7.8%), 
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and 7.1% (95% CI=6.7%, 7.5%), respectively. By insurance type, the estimated proportions 
of breast cancer cases attributed to alcohol were larger among privately insured younger 
women than those enrolled in Medicaid, but the Medicaid versus private insurance 
difference in AAF was minimal for older women. Additional details on the estimated results 
of AAF for the various age groups, race/ethnicity, and insurance status are presented in 
Appendix Tables 4 and 5 (available online).
The estimated total annual number of breast cancer incident cases attributable to alcohol 
consumption among younger women with Medicaid was 253 (95% CI=220, 288) (Table 2). 
These alcohol-attributable breast cancer incident cases accounted for an estimated annual 
medical care costs of $14.5 million (95% CI=$12.6 million, $16.6 million) (Table 2). 
Among the privately insured, the estimated total number of breast cancer incident cases was 
1,383 (95% CI=1,325, 1,438), accounting for an estimated $133.9 million (95% CI= $126.5 
million, $141.3 million) in annual medical care costs. Combining the health outcomes 
associated with alcohol consumption for Medicaid beneficiaries and privately insured 
younger women, 1,636 (95% CI=1,570, 1,703) breast cancer incident cases were attributable 
to alcohol consumption, accounting for an estimated $148.4 million (95% CI=$140.6 
million, $156.1 million) in annual medical care costs. Across both insurance categories, the 
attributable incident cases were higher at the localized stage, with progressively smaller 
numbers at the regional and distant stages. However, the estimated annual medical care costs 
were higher for regional stage, particularly in privately insured women ($63.9 million) and 
in the combined Medicaid and private insurance ($71.0 million) than in the local stage 
($60.6 million) and ($65.7 million), respectively (Table 2). The estimated incident cases and 
medical care costs of breast cancer attributable to alcohol consumption for older women are 
presented in Appendix Table 6 (available online).
DISCUSSION
In this paper, the authors estimated the number of breast cancer incident cases attributable to 
alcohol consumption among women aged <45 years and the annual medical care costs for 
these alcohol-attributable breast cancers based on their health insurance coverage (i.e., 
Medicaid, private insurance, and both groups together). The AAF of breast cancer incident 
cases was 1.8, 6.6, and 5.2 percentage points higher in younger than older women enrolled 
in Medicaid, privately insured, or a combination of both groups, respectively. The higher 
percentages observed in younger women are consistent with reports that younger women are 
more likely to consume alcohol and to binge drink than older women,18 which was used as a 
comparison group in this study.
As stated earlier, alcohol use and binge drinking among younger women is a public health 
problem. A review study indicated that alcohol use and binge drinking is one of the factors 
that could increase the chances of breast cancer among younger women.17 According to the 
estimates reported in this paper, one in 12, one in seven, or one in eight breast cancer 
incident cases occurring in younger women enrolled in Medicaid, privately insured, or 
combination of both groups, respectively, are associated with alcohol consumption. These 
estimates are significantly lower in older women, estimated to be one in 15 for those 
Ekwueme et al. Page 5
Am J Prev Med. Author manuscript; available in PMC 2018 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
enrolled in Medicaid and approximately one in 14 for those in privately insured or both 
insurance groups together.
In general, the estimated alcohol-attributable breast cancer incident cases and the associated 
annual medical care costs for privately insured younger women were significantly (p<0.05) 
higher than the incident cases for Medicaid-insured women. There are several potential 
explanations for this outcome. First, there are more women enrolled in private insurance 
than in Medicaid. Second, the estimated AAF of breast cancer incident cases is much 
smaller among women enrolled in Med-icaid than those privately insured. This may be 
explained by the fact that the prevalence and distribution of alcohol consumption is higher in 
high-income households compared with women in low-income households.18,39 For 
example, a CDC study reported that alcohol use and binge drinking was most prevalent 
among young women from households with annual incomes of ≥$75,00018 when compared 
with those whose incomes are below the poverty line.41 Third, private health insurers tend to 
reimburse healthcare providers at a substantially higher rate than the reimbursement rate in 
Medicaid programs.40
The estimates reported in this paper indicate the medical care costs of treating breast cancer 
incident cases attributable to alcohol consumption are nearly $150 million per year. These 
treatment costs are substantial. However, the cancer impact of alcohol consumption among 
younger women is not limited to breast cancer; alcohol consumption also has been linked to 
cancers of the liver, mouth, pharynx, larynx, esophagus, and uterus.41–46 In addition, intake 
of alcoholic beverages and binge drinking may be associated with other health, social, and 
behavioral consequences that adversely affect young women, such as unintended pregnancy, 
sexually transmitted diseases, and heart disease.18,20,47
Interventions designed to reduce alcohol consumption among young women, such as those 
recommended by the U.S. Preventive Services Task Force and the Community Preventive 
Services Task Force, are expected to reduce the frequency, intensity, and excessive alcohol 
consumption and related harms, including healthcare costs related to the treatment of 
alcohol-attributable conditions.48–50 In addition to the evidence-based clinical and 
community intervention strategies recommended by the U.S. Preventive Services Task Force 
and the Community Preventive Services Task Force to reducing alcohol consumption 
particularly among women and girls, there are many factors that can influence a woman’s 
risk of breast cancer over her lifetime, and the timing of exposures to carcinogens and 
chemicals that act as endocrine disruptors influence lifetime breast cancer risk.51,52 Other 
factors that can increase breast cancer risk include weight gain during adult life, combined 
estrogen and progestin hormone therapy, and physical inactivity.53
As reported in this paper, the estimated total annual medical care cost among younger 
women with breast cancer attributable to alcohol consumption was nearly $150 million per 
year. These treatment costs could be reduced if recommended evidence-based intervention 
strategies were effectively implemented. For example, clinicians could adopt some of the 
recommended interventions, such as screening and behavioral counseling, which may 
include discussing the negative consequences of alcohol intake. Further, adoption of other 
Community Preventive Services Task Force evidence-based recommendations, such as 
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increasing the unit price of alcohol through an increase in excise tax, has been demonstrated 
to be effective and economically efficient to decrease the demand for excessive alcohol 
consumption, as well as to decrease alcohol-related outcomes.50 Similarly, conducting 
alcohol screening and brief intervention with patients could help to reduce patients’ cancer 
risk.54 The implementation of these interventions could contribute to the prevention of 
alcohol-attributable breast cancer and the associated treatment costs in younger women.
Limitations
This study has several limitations. First, the findings reported in this paper are based on the 
assessment of alcohol consumption at a point in time. An ideal approach would be to model 
a lifetime risk of alcohol consumption among younger women and its impact on breast 
cancer. As a result, the estimated AAF may be overstated. However, in the study, the 
assumption was that regardless of the level of drinking, there is a risk of developing breast 
cancer.33,34 Second, the results presented in this paper are based on the estimate of the AAF; 
however, development of breast cancer is a result from a complex interplay of factors rather 
than from a single factor. Some of these risk factors are physical inactivity45 and obesity,55 
which are often associated with excessive alcohol use,56,57 later age at first birth,58 and 
family history of breast cancer.59 This has important implications regarding the 
interpretation of the AAFs and associated attributable cases and medical care costs. 
Specifically, these results do not distinguish between breast cancer cases that could be 
eliminated by removing alcohol exposure only versus cases that could be eliminated by 
removing alcohol exposure or by removing exposure to one or more of the alternative 
causative factors. Third, currently there is no RR of breast cancer for younger women by 
alcohol consumption status. As a result, RR estimates of breast cancer for women of all ages 
were used. Therefore, the impact of this limitation depends on the shape of the dose–
response curve with regard to alcohol use as women age. Fourth, it is well documented that 
breast cancer has multiple subtypes.60 The estimates reported in this paper did not 
distinguish which breast cancer subtype is most susceptible to alcohol consumption. Studies 
have reported that even with a moderate amount of consumed alcohol, women are at 
increased risk of estrogen receptor–positive/ progesterone receptor–positive breast cancer.
10,14,61,62
 Fifth, currently in the literature there are limited data on incident-based breast 
cancer costs by stage at diagnosis for younger women. Therefore, the cost data used in this 
paper were obtained from two recent studies that estimated medical costs of treating breast 
cancer among younger Medicaid beneficiaries and privately insured women in North 
Carolina, and their generalizability may be limited (J Trogdon, University of North Carolina 
at Chapel Hill, unpublished observations, 2017).27 However, the authors note that private 
insurance and Medicaid cancer treatment costs in North Carolina are close to median cancer 
treatment costs across the country.63 Finally, the reported costs only focused on healthcare 
costs from Medicaid beneficiaries and the privately insured, and did not account for the 
broader costs and consequences of alcohol consumption, such as medical costs for uninsured 
women or those with other insurance, productivity and mortality costs associated with breast 
cancer among younger women,64,65 and costs of non-cancer–related alcohol-induced harms. 
Therefore, the economic cost associated with alcohol consumption reported in this paper 
likely underestimates the true cost.
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CONCLUSIONS
The alcohol-attributable breast cancer cases and medical care costs of nearly $150 million 
per year for treating these incident cases reported in this paper may have far-reaching 
consequences to younger women and society in general. These women could spend years 
living with clinical, reproductive, physical, social, and emotional effects of breast cancer 
diagnosis and its treatment, which may lead to loss of economic well-being and shortened 
life expectancy. Alcohol use is potentially a modifiable behavior. The data reported in this 
paper suggest a substantial benefit from increased use of already existing effective evidence-
based interventions to address and reduce alcohol consumption in younger women.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Alcohol-attributable Fractions of Breast Cancer Cases by Insurance Status
Variable Younger women,a % Older women,b %
Medicaid 8.71c (7.41, 10.00) 6.88d (6.23, 7.51)
Private insurance 13.83c (13.30, 14.37) 7.26d (6.77, 7.81)
Combination of Medicaid and private insurance 12.27c (11.41, 13.11) 7.09d (6.69, 7.51)
Note: Values are estimate (95% CI). Estimates in boldface are statistically significantly different from zero (p<0.05).
aAged 18–44 years.
bAged 45–64 years.
c
The estimate for younger women is statistically significantly different (p<0.05) from the corresponding estimate for older women.
d
The estimate for women enrolled in Medicaid is statistically significantly different (p<0.05) from the corresponding estimate for women with 
private health insurance.
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Table 2
Alcohol-attributable Breast Cancer Incidence Cases and Medical Care Costs in Younger Women by Stage at 
Diagnosis and Insurance Status
Variable Medicaid insurance Private insurance Medicaid and private insurance
No. of alcohol-attributable breast cancer incidence cases
 Localized 110a,b (95, 125) 763a,b (731, 794) 873 (839, 907)
 Regional 119a,b (104, 136) 554a,b (531, 576) 673 (646, 701)
 Distant 25a,b (21, 28) 66a,b (63, 68) 90 (86, 95)
 Overall 253a,b (220, 288) 1,383a,b (1,325, 1,438) 1,636 (1,570, 1,703)
Attributable annual medical care costs (in millions $)
 Localized 5.11a,b (4.39, 5.91) 60.60a,b (56.44, 64.82) 65.72 (61.56, 70.06)
 Regional 7.08a,b (6.08, 8.15) 63.93a,b (59.81, 68.07) 71.01 (66.93, 75.25)
 Distant 2.30a,b (1.93, 2.69) 9.36a,b (7.79, 11.16) 11.66 (10.01, 13.48)
 Overall 14.50a,b (12.61, 16.57) 133.90a,b (126.50, 141.30) 148.40 (140.60, 156.10)
Note: Values are estimate (95% CI). Estimates in boldface are statistically significantly different from zero (p<0.05).
a
The estimate for younger women (aged 18–44 years) is statistically significantly different (p<0.05) from the corresponding estimate for older 
women (aged 45–64 years). Estimates for older women are presented in Appendix Table 6 (available online).
b
The estimate for women enrolled in Medicaid is statistically significantly different (p<0.05) from the corresponding estimate for women with 
private health insurance.
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